← Eichor
Condition: Idiopathic Inflammatory Myopathies Iim Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Idiopathic Inflammatory Myopathies Iim

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
Phase 1 · 14 location(s) · CRISPR Therapeutics · NCT06925542Optimizing Treatment on Idiopathic Inflammatory Myopathies
Phase N/A · 1 location(s) · University of Sao Paulo · NCT03092180Safety and Efficacy of ULSC on Disease Severity and Steroid Tapering in Participants With Dermatomyositis/ Polymyositis
Phase 2/Phase 3 · 2 location(s) · Restem, LLC. · NCT07160205A Study of OL-108 in Relapsed/Refractory Autoimmune Diseases
Phase 1 · 2 location(s) · Beijing GoBroad Hospital · NCT06980597Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases
Phase 1/Phase 2 · 1 location(s) · Tianjin Medical University General Hospital · NCT07022197A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants Wit
Phase 1 · 37 location(s) · AstraZeneca · NCT06916806GC012F Injection in Refractory Idiopathic Inflammatory Myopathy
EARLY_Phase 1 · 1 location(s) · Daishi Tian · NCT07086404A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD)
Phase 1 · 19 location(s) · GlaxoSmithKline · NCT07371468Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy
Phase 2 · 8 location(s) · National Institute of Allergy and Infectious Diseases (NIAID · NCT07103746CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases
Phase 1 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07315087A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathie
Phase 3 · 146 location(s) · Pfizer · NCT05895786A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Disease
Phase 1 · 28 location(s) · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · NCT07115745A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With
Phase 1 · 14 location(s) · Allogene Therapeutics · NCT07085104Anti-CD19 IL-10/IL15 CAR-NK Cells in Refractory/Relapsed Autoimmune Diseases
NA · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT06614270OM336 in Seropositive Autoimmune Diseases
Phase 1 · 1 location(s) · Lakefront Biotherapeutics West LLC · NCT07229144Adult Autoimmune Myopathies (MAIA)
NA · 1 location(s) · University Hospital, Brest · NCT04792931MTS109 in Patients With Refractory Autoimmune Diseases
EARLY_Phase 1 · 1 location(s) · Shanghai Changzheng Hospital · NCT07526350Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body Myositis
EARLY_Phase 1 · 2 location(s) · Austin Neuromuscular Center · NCT06479863A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Autoimmune Diseases
Phase 1 · 1 location(s) · Xencor, Inc. · NCT07284797AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Stud
Phase 2 · 52 location(s) · Artiva Biotherapeutics, Inc. · NCT06991114A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies
Phase 3 · 24 location(s) · Pfizer · NCT06698796A Study of LUCAR-G79D in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE) and Idiopathic Inflamm
Phase 1 · 5 location(s) · Nanjing Legend Biotech Co. · NCT07331272A Study of AZD0120 in Autoimmune Diseases
Phase 1 · 22 location(s) · AstraZeneca · NCT07295847A Study of CC312 for Relapsed/Refractory Autoimmune Diseases
EARLY_Phase 1 · 1 location(s) · CytoCares Inc · NCT07193810A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Brea
Phase 1 · 54 location(s) · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · NCT05869955An Exploratory Study of CD19/CD22/BCMA CAR-T Cells (BZE2204) in Subjects With Relapsed or Refractory Autoimmune Diseases
EARLY_Phase 1 · 1 location(s) · Shanghai Cell Therapy Group Co.,Ltd · NCT07174843Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases
Phase 2 · 6 location(s) · UMC Utrecht · NCT06285539Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous Sys
EARLY_Phase 1 · 1 location(s) · Tongji Hospital · NCT04561557Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Media
Phase 1 · 1 location(s) · Tongji Hospital · NCT07526493EACVI Study on Multimodality Cardiovascular Imaging of Inflammatory Cardiovascular Diseases
Phase N/A · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT07077304
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.